Literature DB >> 34320283

An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.

Billy Dunn1, Peter Stein1, Robert Temple1, Patrizia Cavazzoni1.   

Abstract

Entities:  

Year:  2021        PMID： 34320283     DOI： 10.1056/NEJMc2111960

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab.

Authors:  Emily A Largent; Andrew Peterson; Jason Karlawish; Holly Fernandez Lynch
Journal:  Drugs Aging       Date:  2022-06-13       Impact factor: 4.271

2.  Expedited regulatory product approval in the time of COVID-19.

Authors:  Gary D Novack
Journal:  Ocul Surf       Date:  2022-05-28       Impact factor: 6.268

Review 3.  The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.

Authors:  Eric Karran; Bart De Strooper
Journal:  Nat Rev Drug Discov       Date:  2022-02-17       Impact factor: 112.288

4.  Design, Synthesis and Biological Evaluation of New 3,4-Dihydro-2(1H)-Quinolinone-Dithiocarbamate Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease.

Authors:  Jie Guo; Airen Xu; Maojun Cheng; Yang Wan; Rikang Wang; Yuanying Fang; Yi Jin; Sai-Sai Xie; Jing Liu
Journal:  Drug Des Devel Ther       Date:  2022-05-18       Impact factor: 4.319

Review 5.  The Multifaceted Role of Neuroprotective Plants in Alzheimer's Disease Treatment.

Authors:  Tarek Zieneldien; Janice Kim; Chuanhai Cao
Journal:  Geriatrics (Basel)       Date:  2022-02-26

6.  Commentary on: A call for better reporting of trials using surrogate primary endpoints.

Authors:  Jeffrey Cummings
Journal:  Alzheimers Dement (N Y)       Date:  2022-07-26

7.  Weakly activated core neuroinflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer's disease.

Authors:  Fuhai Li; Abdallah M Eteleeb; William Buchser; Christopher Sohn; Guoqiao Wang; Chengjie Xiong; Philip R Payne; Eric McDade; Celeste M Karch; Oscar Harari; Carlos Cruchaga
Journal:  Front Aging Neurosci       Date:  2022-09-27       Impact factor: 5.702

8.  Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.

Authors:  Eleonora Lacorte; Antonio Ancidoni; Valerio Zaccaria; Giulia Remoli; Leonardo Tariciotti; Guido Bellomo; Francesco Sciancalepore; Massimo Corbo; Flavia L Lombardo; Ilaria Bacigalupo; Marco Canevelli; Paola Piscopo; Nicola Vanacore
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 9.  Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders.

Authors:  Amaresh K Ranjan; Anil Gulati
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.